Core Viewpoint - XuanZhu Bio (02575) has seen a significant stock price increase of nearly 150% from its IPO price of HKD 11.6, closing at HKD 28.46 with a trading volume of HKD 56.32 million [1] Company Overview - XuanZhu Bio is an innovation-driven biopharmaceutical company based in China, actively developing over ten drug assets targeting digestive system diseases, tumors, and non-alcoholic fatty liver disease (NASH) [1] - The company has three NDA-approved assets, one drug project in the NDA registration stage, one in Phase III clinical trials, four in Phase I clinical trials, and five that have received IND approval [1] Fund Utilization - The net proceeds from the global offering amount to approximately HKD 701 million, with planned allocations as follows: - About 45% for the research and commercialization of core products (KBP-3571, XZP-3287, and XZP-3621) [1] - Approximately 14% for the research of key products (KM602, KM501, XZP-7797, and XZP-6924) [1] - Around 11% for funding other candidate drugs (including XZB-0004, XZP-5610, XZP-6019, and XZP-6877) [1] - About 20% to enhance commercialization and marketing capabilities, particularly through expanding sales and marketing teams [1] - Approximately 10% for working capital and other general corporate purposes [1]
港股异动 | 轩竹生物(02575)尾盘涨超8% 较招股价涨近150% 公司拥超过十余种正在研...